March 2010
Authors : Harish Kavirajan
Affliation : VA Greater Los Angeles Healthcare System and UCLA, Department of Psychiatry and Behavioral Sciences, 950 South Coast Drive, Ste 202, Costa Mesa, Los Angeles, CA 92626, USA ; ; hkaviraj@gmail.com
DOI : 10.1517/14740330802528420
Published in : Expert Opin. Drug Saf.
Subject: Drug Safety Evaluation
Keywords: age-associated memory impairment , alcohol dependence , Alzheimer's , amyotropic lateral sclerosis , attention deficit hyperactivity disorder , autism , bipolar disorder , cholinesterase inhibitor , cocaine dependence , dementia , frontotemporal dementia , glaucoma , headache , Huntington's disease , major depression , memantine , migraine , neuropathic pain , nicotine dependence , nystagmus , obsessive–compulsive disorder , opiate dependence , pervasive development disorder , phantom limb pain , pharmacology , postherpetic neuralgia , post-traumatic stress disorder , safety , schizophrenia , substance abuse , vascular dementia
Please Login to read the full article.
- Orexigen to file obesity drug Contrave after positive Phase III data
- Medivation/Pfizer's disappointing Dimebon data sends Alzheimer's hopes, and shares, crashing
- Alzheimer's conference gives closer look at new compounds
- US FDA approves King's Embeda as abuse-resistant painkiller
